{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T20:34:56Z","timestamp":1793046896317,"version":"4.5.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013220","name":"Ultragenyx Pharmaceutical Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013220","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Advances"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.omta.2026.201840","type":"journal-article","created":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T00:01:24Z","timestamp":1788566484000},"page":"201840","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Management of acute infusion-related reactions in AAV gene therapy guided by mechanistic insight"],"prefix":"10.1016","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0969-6131","authenticated-orcid":false,"given":"Barbara A.","family":"Sullivan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Collis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhea","family":"Cahayag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hector M.","family":"Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Grace","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emil D.","family":"Kakkis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syeda","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danny","family":"Bega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margo Sheck","family":"Breilyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew A.","family":"Grimm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omta.2026.201840_bib5","series-title":"US Prescribing Information","year":"2024"},{"key":"10.1016\/j.omta.2026.201840_bib6","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000213899","article-title":"Reduction of Preexisting AAV9 Antibody Titers Before Onasemnogene Abeparvovec Administration in Twins With Spinal Muscular Atrophy","volume":"105","author":"Nelson","year":"2025","journal-title":"Neurology"},{"key":"10.1016\/j.omta.2026.201840_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.102922","article-title":"Management of infusion-related reactions in cancer therapy: strategies and challenges","volume":"9","author":"Barroso","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.omta.2026.201840_bib8","article-title":"NobelPrize.org","year":"2026","journal-title":"Nobel Prize Outreach"},{"key":"10.1016\/j.omta.2026.201840_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1398-9995.2010.02422.x","article-title":"Anaphylaxis: past, present and future","volume":"66","author":"Ben-Shoshan","year":"2011","journal-title":"Allergy"},{"key":"10.1016\/j.omta.2026.201840_bib10","first-page":"765","article-title":"M\u00e9thode pour pr\u00e9venir la rage apr\u00e8s morsure","volume":"101","author":"Pasteur","year":"1885","journal-title":"Comptes Rendus des S\u00e9ances de l\u2019Acad\u00e9mie des Sciences"},{"key":"10.1016\/j.omta.2026.201840_bib11","article-title":"Developments in Rabies Vaccines: The Path Traversed from Pasteur to the Modern Era of Immunization","volume":"11","author":"Natesan","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.omta.2026.201840_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.waojou.2020.100472","article-title":"World allergy organization anaphylaxis guidance 2020","volume":"13","author":"Cardona","year":"2020","journal-title":"World Allergy Organ. J."},{"key":"10.1016\/j.omta.2026.201840_bib13","series-title":"Cellular and Molecular Immunology, 10e, South Asia Edition-E-Book","author":"Abbas","year":"2021"},{"key":"10.1016\/j.omta.2026.201840_bib14","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.jaci.2005.12.1303","article-title":"Second symposium on the definition and management of anaphylaxis: summary report--Second National Institute of Allergy and Infectious Disease\/Food Allergy and Anaphylaxis Network symposium","volume":"117","author":"Sampson","year":"2006","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.omta.2026.201840_bib16","doi-asserted-by":"crossref","DOI":"10.1002\/jimd.70241","article-title":"Phase 3 Randomized Trial Results of DTX401 AAV Gene Therapy for the Treatment of GSDIa","volume":"49","author":"Mitchell","year":"2026","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.omta.2026.201840_bib17","doi-asserted-by":"crossref","DOI":"10.1002\/jimd.70014","article-title":"Safety and Efficacy of DTX401, an AAV8-Mediated Liver-Directed Gene Therapy, in Adults With Glycogen Storage Disease Type I a (GSDIa)","volume":"48","author":"Weinstein","year":"2025","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.omta.2026.201840_bib18","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S0161-5890(02)00254-7","article-title":"Functional characterization of the lectin pathway of complement in human serum","volume":"39","author":"Roos","year":"2003","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.omta.2026.201840_bib19","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jim.2004.11.016","article-title":"Functional analysis of the classical, alternative, and MBL pathways of the complement system: standardization and validation of a simple ELISA","volume":"296","author":"Seelen","year":"2005","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.omta.2026.201840_bib20","series-title":"The Complement System. Methods in Molecular Biology, vol 1100","article-title":"Evaluation of Complement Function by ELISA","author":"Roos","year":"2014"},{"key":"10.1016\/j.omta.2026.201840_bib22","series-title":"The effects of sub-optimal sample handling on multiple complement measurements: Is there a potential signature of mishandling? Workshop on Recent Issues in Bioanalysis (WRIB)","author":"Cynthia Marschner","year":"2018"},{"key":"10.1016\/j.omta.2026.201840_bib23","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/7045630","article-title":"Mannose-Binding Lectin: Biologic Characteristics and Role in the Susceptibility to Infections and Ischemia-Reperfusion Related Injury in Critically Ill Neonates","volume":"2017","author":"Auriti","year":"2017","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.omta.2026.201840_bib24","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.bbadis.2004.02.005","article-title":"Causative factors behind poloxamer 188 (Pluronic F68, Flocor)-induced complement activation in human sera. A protective role against poloxamer-mediated complement activation by elevated serum lipoprotein levels","volume":"1689","author":"Moghimi","year":"2004","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.omta.2026.201840_bib25","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/BF00509233","article-title":"Involvement of complement in psoriasis and atopic dermatitis--measurement of C3a and C5a, C3, C4 and C1 inactivator","volume":"277","author":"Kapp","year":"1985","journal-title":"Arch. Dermatol. Res."},{"key":"10.1016\/j.omta.2026.201840_bib26","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1056\/NEJM198706253162603","article-title":"Tryptase levels as an indicator of mast-cell activation in systemic anaphylaxis and mastocytosis","volume":"316","author":"Schwartz","year":"1987","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omta.2026.201840_bib27","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.anai.2022.08.996","article-title":"Tryptase in type I hypersensitivity","volume":"130","author":"Michel","year":"2023","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"10.1016\/j.omta.2026.201840_bib28","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.iac.2006.05.010","article-title":"Diagnostic value of tryptase in anaphylaxis and mastocytosis","volume":"26","author":"Schwartz","year":"2006","journal-title":"Immunol. Allergy Clin. North Am."},{"key":"10.1016\/j.omta.2026.201840_bib29","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/j.jaci.2006.03.031","article-title":"Mast cell biology in evolution","volume":"117","author":"Metcalfe","year":"2006","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.omta.2026.201840_bib30","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1016\/j.jaip.2020.08.006","article-title":"Practical Guidance for the Evaluation and Management of Drug Hypersensitivity: Specific Drugs","volume":"8","author":"Broyles","year":"2020","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"10.1016\/j.omta.2026.201840_bib31","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.jaci.2007.05.001","article-title":"Risk assessment in anaphylaxis: current and future approaches","volume":"120","author":"Simons","year":"2007","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.omta.2026.201840_bib34","series-title":"Tryptase - Test Code - 34484","author":"Diagnostics","year":"2025"},{"key":"10.1016\/j.omta.2026.201840_bib35","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1159\/000501079","article-title":"Why the 20% + 2 Tryptase Formula Is a Diagnostic Gold Standard for Severe Systemic Mast Cell Activation and Mast Cell Activation Syndrome","volume":"180","author":"Valent","year":"2019","journal-title":"Int. Arch. Allergy Immunol."},{"key":"10.1016\/j.omta.2026.201840_bib36","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1111\/all.12142","article-title":"Skin test concentrations for systemically administered drugs -- an ENDA\/EAACI Drug Allergy Interest Group position paper","volume":"68","author":"Brockow","year":"2013","journal-title":"Allergy"},{"key":"10.1016\/j.omta.2026.201840_bib37","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.iac.2021.12.008","article-title":"Anaphylaxis to Excipients in Current Clinical Practice: Evaluation and Management","volume":"42","author":"Bruusgaard-Mouritsen","year":"2022","journal-title":"Immunol. Allergy Clin. North Am."},{"key":"10.1016\/j.omta.2026.201840_bib38","author":"Laboratories"},{"key":"10.1016\/j.omta.2026.201840_bib39","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/ni.1923","article-title":"Complement: a key system for immune surveillance and homeostasis","volume":"11","author":"Ricklin","year":"2010","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.omta.2026.201840_bib40","article-title":"Granzyme K drives a newly-intentified pathway of complement activation","author":"Donado","year":"2024","journal-title":"bioRxiv"},{"key":"10.1016\/j.omta.2026.201840_bib41","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1055\/s-2007-1007206","article-title":"Complement and complement deficiencies","volume":"17","author":"Whaley","year":"1997","journal-title":"Semin. Liver Dis."},{"key":"10.1016\/j.omta.2026.201840_bib42","first-page":"1370","article-title":"Adeno-Associated Virus Vector Gene Delivery Elevates Factor I Levels and Downregulates the Complement Alternative Pathway In Vivo","volume":"32","author":"Ahmad","year":"2021","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omta.2026.201840_bib43","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1084\/jem.151.3.501","article-title":"Biosynthesis of the complement components and the regulatory proteins of the alternative complement pathway by human peripheral blood monocytes","volume":"151","author":"Whaley","year":"1980","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.omta.2026.201840_bib44","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/cmi.2015.97","article-title":"Hepatocytes: a key cell type for innate immunity","volume":"13","author":"Zhou","year":"2016","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.omta.2026.201840_bib45","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1046\/j.1523-1747.2000.00841.x","article-title":"Synthesis of complement components C3 and factor B in human keratinocytes is differentially regulated by cytokines","volume":"114","author":"Pasch","year":"2000","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.omta.2026.201840_bib46","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/eji.1830220131","article-title":"In vitro biosynthesis of complement factor I by human endothelial cells","volume":"22","author":"Julen","year":"1992","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.omta.2026.201840_bib47","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/S0167-4781(98)00189-4","article-title":"Transcriptional and post-transcriptional regulation of complement factor I (CFI) gene expression in Hep G2 cells by interleukin-6","volume":"1442","author":"Minta","year":"1998","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.omta.2026.201840_bib48","first-page":"109","article-title":"The influence of C3b inactivator (KAF) concentration on the ability of serum to support complement activation","volume":"21","author":"Lachmann","year":"1975","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.omta.2026.201840_bib49","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.999021","article-title":"Pre-existing humoral immunity and complement pathway contribute to immunogenicity of adeno-associated virus (AAV) vector in human blood","volume":"13","author":"Smith","year":"2022","journal-title":"Front. Immunol."}],"container-title":["Molecular Therapy Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3117387X26001758?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3117387X26001758?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T19:38:23Z","timestamp":1793043503000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S3117387X26001758"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["S3117387X26001758"],"URL":"https:\/\/doi.org\/10.1016\/j.omta.2026.201840","relation":{},"ISSN":["3117-387X"],"issn-type":[{"value":"3117-387X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of acute infusion-related reactions in AAV gene therapy guided by mechanistic insight","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omta.2026.201840","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"201840"}}